Loading
TR
Tabula Rasa HealthCare, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Cancro Thomas, was filed 14 Dec 2022.
Tabula Rasa HealthCare, Inc.: what insiders have been doing
Every trade that managers of Tabula Rasa HealthCare, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Tabula Rasa HealthCare, Inc. The previous disclosure was published on 14 November 2023.
The full history, which starts in 2016, counts 28 purchases against 408 sales.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
1,116
Thresholds
n/a
Buy Volume
€7M
28 ops. · all time
Sell Volume
€119M
408 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$257.9M
Gross profitUS$24.9M10% margin
Net income-US$127M-49.2% margin
Last declaration on 14 November 2023
Declarations1,116 total
50,169 sharesCommon StockSEC:0001415889-23-015112:1
25,641 sharesCommon StockSEC:0001415889-23-015112:2
25,641 sharesCommon StockSEC:0001415889-23-015114:1
50,808 sharesCommon StockSEC:0001415889-23-015131:1
25,641 sharesCommon StockSEC:0001415889-23-015127:1
9,784 sharesCommon StockSEC:0001415889-23-015127:2
38,194 sharesCommon StockSEC:0001415889-23-015110:1
12,960 sharesCommon StockSEC:0001415889-23-015123:1
1,350 sharesCommon StockSEC:0001415889-23-015123:2
60,806 sharesCommon StockSEC:0001415889-23-015129:1
41,667 sharesCommon StockSEC:0001415889-23-015121:1
130,234 sharesCommon StockSEC:0001415889-23-015121:2
221,875 sharesCommon StockSEC:0001415889-23-015121:3
3,792 sharesCommon StockSEC:0001415889-23-015125:1
25,641 sharesCommon StockSEC:0001415889-23-015125:2
37,037 sharesCommon StockSEC:0001415889-23-015100:1
150,000 sharesCommon StockSEC:0001415889-23-015100:2
55,555 sharesCommon StockSEC:0001415889-23-015100:3
61,436 sharesCommon StockSEC:0001415889-23-015133:1
6,599,966 shares@ US$10.5098.6% of flowCommon StockSEC:0000921895-23-002642:0
17,896 sharesCommon StockSEC:0001415889-23-015133:0
20,879 sharesCommon StockSEC:0001415889-23-015112:0
88,514 sharesCommon StockSEC:0001415889-23-015131:0
61,500 sharesCommon StockSEC:0001415889-23-015100:0
249,477 sharesCommon StockSEC:0001415889-23-015119:0
25 of 1116 declarations
About Tabula Rasa HealthCare, Inc.
Tabula Rasa HealthCare, Inc. (TRHC) is a U.S.-listed healthcare company traded on NASDAQ, with headquarters in New Jersey, United States. From an international equity-investor perspective, the company sits in the healthcare technology and pharmacy services segment, combining software, clinical services, and medication management capabilities. TRHC originally built its franchise around medication safety: helping prescribers, pharmacists, and patients optimize drug regimens, reduce adverse drug events, and improve outcomes. Over time, the company evolved from a narrower medication-safety platform into a more integrated care-management and pharmacy services business. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651561/000155837023013894/trhc-20230630x10q.htm?utm_source=openai))
Its current business model is focused on personalized, precision medication management and pharmacy fulfillment for complex patient populations. According to SEC disclosures, the company provides medication fulfillment services, cloud-based software, pharmacy benefit management solutions, and clinical pharmacist services at the point of care. That makes TRHC a niche operator serving health plans and at-risk provider groups, particularly organizations involved in value-based care and PACE-related programs. In competitive terms, TRHC is not a mass-market pharmacy chain or a large diversified healthcare conglomerate; instead, it targets a specific and operationally demanding slice of the U.S. healthcare ecosystem. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651561/000155837023013894/trhc-20230630x10q.htm?utm_source=openai))
Read moreShow less
A major strategic theme in recent years has been portfolio simplification. TRHC sold PrescribeWellness in 2022 and completed the divestiture of SinfoníaRx and DoseMeRx in 2023, using those transactions to sharpen its focus on core pharmacy-care management markets. This restructuring was important because it reduced business complexity and signaled a deliberate shift toward a more concentrated operating model. The company has also highlighted multi-year customer relationships, including a five-year contract extension with Trinity Health PACE, which underscores the recurring, contract-based nature of part of its revenue base. ([nasdaq.com](https://www.nasdaq.com/press-release/tabula-rasa-healthcare-agrees-to-sell-its-prescribewellness-business-to-transaction?utm_source=openai))
TRHC’s competitive strength lies in its specialized workflow, clinical expertise, and technology-enabled service stack. Its platform is designed for patients with high medication burden and multiple chronic conditions, a segment where medication adherence, safety, and cost control are especially important. The company’s footprint is predominantly in the United States, and its business is closely tied to domestic healthcare reimbursement and managed-care dynamics. Another notable recent development was the announced acquisition by Nautic Partners in 2023, followed by a planned combination with ExactCare Pharmacy, which materially changed the company’s strategic outlook and market perception. Overall, TRHC is best viewed as a U.S. specialty healthcare technology and pharmacy services platform with a focused operating profile and an M&A-shaped recent history. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651561/000114036123050520/ef20013655_ex99-1.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
